TEVA · Teva Pharmaceutical Industries Ltd · Webcasts, Transcripts & Audio
$42.62
+0.05 (+0.12%)
At close · Nov 17
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$49.73B
Shares
1.17B
Volume · Nov 17
7.02M
Avg daily vol (3M)
6.16M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Teva Pharmaceutical Industries Ltd Webcasts
Earnings calls, investor updates, investor days and conferences for Teva Pharmaceutical Industries Ltd (TEVA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Transcript
Confident tone
Access, litigation and program risks
Biopharma transformation and margins
Neuroscience launches and pipeline
Revenue
$4.39B
▼ 1.9% YoY Diluted EPS
$0.20
▼ 45.9% YoY Gross margin
55.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-10-09
Teva Pharmaceutical Industries Ltd (TEVA) October 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-23
Teva Pharmaceutical Industries Ltd (TEVA) September 23, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-22
Teva Pharmaceutical Industries Ltd (TEVA) September 22, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-22
Teva Pharmaceutical Industries Ltd (TEVA) September 22, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Teva Pharmaceutical Industries Ltd (TEVA) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-29
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Transcript
Confident tone
Pipeline launches (olanzapine, Ecopipam) and milestones
Innovative portfolio growth (Austedo, Ajovy, Uzedy)
2026 guidance raise
Revenue
$4.14B
▼ 0.8% YoY Diluted EPS
$-0.49
▼ 304.2% YoY Gross margin
52.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Teva Pharmaceutical Industries Ltd (TEVA) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Teva Pharmaceutical Industries Ltd (TEVA) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Transcript
Confident tone
R&D Pipeline and Readouts
Organizational Effectiveness and Cost Savings
Pivot to Growth Strategy
Revenue
$3.98B
▲ 2.3% YoY Diluted EPS
$0.31
▲ 72.2% YoY Gross margin
49.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Teva Pharmaceutical Industries Ltd (TEVA) March 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-01-28
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2025 Earnings Call Transcript
Confident tone
Business development and capital allocation
Innovative portfolio growth
Generics business stability
Revenue
$1.50B
▼ 64.5% YoY Gross margin
177.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-13
Teva Pharmaceutical Industries Ltd (TEVA) January 13, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-05
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Transcript
Confident tone
AUSTEDO CMS price negotiation and 2027 targets
Cost savings program and operational efficiency
Long-acting injectable (LAI) schizophrenia franchise
Revenue
$4.48B
▲ 3.4% YoY Diluted EPS
$0.37
Gross margin
51.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2025 Earnings Call Transcript
Confident tone
Generics business performance
Biosimilars
R&D pipeline and innovation
Revenue
$4.18B
▲ 0.3% YoY Diluted EPS
$0.24
Gross margin
50.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Transcript
Confident tone
Innovative brands growth
Long-acting injectable franchise in schizophrenia
2027 strategic targets and Pivot to Growth
Revenue
$3.89B
▲ 1.9% YoY Diluted EPS
$0.18
Gross margin
48.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-02-24
Teva Pharmaceutical Industries Ltd (TEVA) February 24, 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-01-29
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Transcript
Confident tone
Financial performance and guidance
Generics and biosimilars
2027 margin targets and operational leverage
Revenue
$4.23B*
▼ 5.1% YoY Gross margin
50.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Transcript
Confident tone
Innovative portfolio growth (AUSTEDO, AJOVY, UZEDY)
TAPI divestment
Generics business
Revenue
$4.33B
▲ 12.5% YoY Diluted EPS
$-0.39
▼ 750% YoY Gross margin
49.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Transcript
Confident tone
R&D pipeline progress (Olanzapine, TL1A, ICS/SABA, MSA)
AUSTEDO performance and IRA considerations
Innovative portfolio: AJOVY, UZEDY, SIMLANDI
Revenue
$4.16B
▲ 7.4% YoY Diluted EPS
$-0.75
Gross margin
48.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2024 Earnings Call Transcript
Confident tone
Biosimilars Launches and Outlook
AUSTEDO Growth and Guidance
Olanzapine LAI Phase III Results
Revenue
$3.82B
▲ 4.3% YoY Diluted EPS
$-0.12
Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-31
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2023 Earnings Call Transcript
Confident tone
Innovative brands: Austedo and Ajovy
New product launches (Uzedy, biosimilars)
Pivot to Growth strategy execution and 2023 results
Revenue
$4.46B*
▲ 14.8% YoY Gross margin
54.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2023 Earnings Call
Revenue
$3.85B
▲ 7.1% YoY Diluted EPS
$0.06
▲ 20% YoY Gross margin
48.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2023 Earnings Call
Revenue
$3.88B
▲ 2.4% YoY Diluted EPS
$-0.78
Gross margin
46.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2023 Earnings Call
Revenue
$3.66B
▲ 0% YoY Diluted EPS
$-0.20
Gross margin
43.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2022 Earnings Call
Revenue
$3.88B*
▼ 5.3% YoY Diluted EPS
$-1.17
Gross margin
45.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2022 Earnings Call
Revenue
$3.60B
▼ 7.5% YoY Diluted EPS
$0.05
▼ 80.8% YoY Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2022 Earnings Call
Revenue
$3.79B
▼ 3.2% YoY Diluted EPS
$-0.23
▼ 221.1% YoY Gross margin
47.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2022 Earnings Call
Revenue
$3.66B
▼ 8.1% YoY Diluted EPS
$-0.86
▼ 1328.6% YoY Gross margin
47.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-09
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2021 Earnings Call
Revenue
$4.10B*
▼ 8% YoY Gross margin
50.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2021 Earnings Call
Revenue
$3.89B
▼ 2.3% YoY Diluted EPS
$0.26
Gross margin
46.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2021 Earnings Call
Revenue
$3.91B
▲ 1% YoY Diluted EPS
$0.19
▲ 46.2% YoY Gross margin
47.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2021 Earnings Call
Revenue
$3.98B
▼ 8.6% YoY Diluted EPS
$0.07
▲ 16.7% YoY Gross margin
47.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2020 Earnings Call
Revenue
$4.45B
▼ 0.3% YoY Diluted EPS
$0.14
▲ 40% YoY Gross margin
46.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2020 Earnings Call
Revenue
$3.98B
▼ 2.8% YoY Diluted EPS
$-3.97
Gross margin
46.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2020 Earnings Call
Revenue
$3.87B
▼ 7.3% YoY Diluted EPS
$0.13
Gross margin
45.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2020 Earnings Call
Revenue
$4.36B
▲ 5% YoY Diluted EPS
$0.06
Gross margin
47.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-12
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2019 Earnings Call
Revenue
$4.47B
▲ 1.1% YoY Diluted EPS
$0.10
Gross margin
43.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–38 of 38 webcasts
Key facts
CIK
818686
CUSIP
M8769Q102
13F (30d)
628 filings
563 filers
Visit website
Investor relations